---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092748"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:40:29.859356+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance

## Summary
- Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.
- Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.
- New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.
- Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.
- Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio.

## SEC filing metadata
- accession: 0001193125-26-092748
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/0001193125-26-092748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/dcoy-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092748
- JSON: https://secwatch.observer/filing/0001193125-26-092748.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.